Description

Technical Parameters

Product Introduction

Dual GLP-1/GIP receptor agonist BGM0504 stands out as a patented molecule renowned for its multifaceted therapeutic benefits. It serves as a cornerstone in the treatment of type 2 diabetes, effectively managing blood glucose levels to promote better health outcomes. Additionally, BGM0504 plays a pivotal role as an anti-obesity medication, facilitating long-term weight management strategies. This dual-purpose medication addresses two prevalent health concerns with its innovative approach, offering patients a comprehensive treatment option that not only targets diabetes but also supports sustained weight loss efforts. Its unique formulation underscores its importance in modern medicine, where managing chronic conditions like diabetes and obesity is crucial for improving overall health and enhancing quality of life.

R&D Development

BGM0504: A Dual Agonist in Clinical Phase Ⅱ

Molecule Design: Introducing a groundbreaking dual agonist with global patent coverage.

As a GLP-1R Agonist

● Clinically validated benefits

Enhanced glycemic control

Weight reduction

Improvement in multiple cardiovascular risk factors

Acting as a GIPR Agonis

● Offers potential advantages

Enhances the efficacy of GLP-1R agonists through diverse pathways

Mitigates emesis and diminishes illness-related behaviors associated with GLP-1R activation

Pre-clinical Data Comparison with Tirzepatide

BGM0504 directly competes with Tirzepatide, demonstrating significant advantages

● In cAMP accumulation assays, BGM0504 shows approximately twice the potency of Tirzepatide.
● - Animal studies highlight BGM0504's superior efficacy and safety over Tirzepatide, with higher NOAEL values for repeated toxicity reported.

Clinical Progress in Phase III

● BGM0504 showcases superior pharmacokinetic characteristics compared to Tirzepatide in healthy volunteers, resulting in higher exposure levels.
● In clinical trials, BGM0504 consistently achieves greater reductions in body weight compared to Tirzepatide at equivalent dosages.
● Having completed Phase II trials, BGM0504 is poised to advance to Phase III studies expected to commence by August 2024.

Certificate Display

product-1561-480

Exhibition Photos

product-1562-559

Company Profile

product-1561-649

FAQ

Q: 1.What do GLP-1 and GIP do?

A: GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption, and assimilation. Recently approved therapeutic agents based on potentiation of incretin action provide new physiologically based approaches for the treatment of type 2 diabetes.

Q: 2.How can I increase my GIP-1 and GIP naturally?

A: Including lean sources of protein, such as poultry, fish, tofu, and legumes, in your meals can help naturally increase GLP-1 levels, leading to improved appetite control and weight management. The message is becoming more and more understood but remember, not all fats are detrimental to weight loss.

Q: 3.Which GLP-1 is best for weight loss?

A: Tirzepatide is the most effective currently available GLP-1 receptor agonist for both glycemic control and weight loss in the short and intermediate term; long-term efficacy and safety are still open questions.

Q: 4.Is metformin a GLP drug?

A: Metformin has a direct and AMPK-dependent effect on GLP-1–secreting L cells and increases postprandial GLP-1 secretion, which seems to contribute to metformin's glucose-lowering effect and mode of action.

Hot Tags: dual glp-1/gip receptor agonist bgm0504, China dual glp-1/gip receptor agonist bgm0504 manufacturers, suppliers, Oseltamivir Phosphate Suspension and Capsule, anti aging ingredient, 9007-28-7, 81065-76-1, 910463 68 2 Oral, Alpha Lipoic Acid Powder

Dual GLP-1/GIP Receptor Agonist BGM0504

R&D Development

FAQ